Toll Free: 1-888-928-9744

USV Limited - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 28 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

USV Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'USV Limited - Product Pipeline Review - 2014', provides an overview of the USV Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of USV Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of USV Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of USV Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the USV Limited's pipeline products

Reasons to buy

- Evaluate USV Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of USV Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the USV Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of USV Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of USV Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of USV Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
USV Limited Snapshot 5
USV Limited Overview 5
Key Information 5
Key Facts 5
USV Limited - Research and Development Overview 6
Key Therapeutic Areas 6
USV Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
USV Limited - Pipeline Products Glance 12
USV Limited - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
USV Limited - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
USV Limited - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
USV Limited - Drug Profiles 15
mitiglinide 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
pegfilgrastim 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
becaplermin 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Epidermal Growth Factor 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
filgrastim 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
glucagon biosimilar 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
USV Limited - Pipeline Analysis 22
USV Limited - Pipeline Products by Target 22
USV Limited - Pipeline Products by Route of Administration 23
USV Limited - Pipeline Products by Molecule Type 24
USV Limited - Pipeline Products by Mechanism of Action 25
USV Limited - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28
List of Tables
USV Limited, Key Information 5
USV Limited, Key Facts 5
USV Limited - Pipeline by Indication, 2014 7
USV Limited - Pipeline by Stage of Development, 2014 8
USV Limited - Monotherapy Products in Pipeline, 2014 9
USV Limited - Partnered Products in Pipeline, 2014 10
USV Limited - Partnered Products/ Combination Treatment Modalities, 2014 11
USV Limited - Phase III, 2014 12
USV Limited - Phase I, 2014 13
USV Limited - Preclinical, 2014 14
USV Limited - Pipeline by Target, 2014 22
USV Limited - Pipeline by Route of Administration, 2014 23
USV Limited - Pipeline by Molecule Type, 2014 24
USV Limited - Pipeline Products by Mechanism of Action, 2014 25 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify